公开(公告)号：US20160039946A1

公开(公告)日：2016-02-11

申请号：US14872290

申请日：2015-10-01

Applicant: Vaccibody AS

Inventor： Bjarne BOGEN ,  Agnete Brunsvik FREDRIKSEN ,  Inger SANDLIE

IPC: C07K16/44 ,  C07K14/34 ,  C12N9/12 ,  C07K14/705 ,  C07K14/715 ,  C07K14/005 ,  C07K16/28

CPC classification number: C07K16/44 ,  A61K2039/505 ,  A61K2039/54 ,  C07K14/005 ,  C07K14/34 ,  C07K14/70578 ,  C07K14/7158 ,  C07K16/28 ,  C07K16/2833 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2319/40 ,  C12N9/1276 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12Y207/07049

Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.

Abstract translation: 公开了触发T细胞和B细胞免疫应答的基于重组抗体的分子。 重组分子由至少一个靶向单元和通过二聚化基序连接的至少一个抗原单元组成。 还公开了编码基于重组抗体的分子的核酸分子和使用基于重组抗体的分子或核酸分子在患者体内治疗多发性骨髓瘤或淋巴瘤的方法。

公开(公告)号：US20160031991A1

公开(公告)日：2016-02-04

申请号：US14776001

申请日：2014-03-13

Applicant: VACCIBODY AS

Inventor： Ole Henrik BREKKE ,  Mona Mari LINDEBERG ,  Agnete Brunsvik FREDRIKSEN

IPC: C07K16/28 ,  C12N7/00 ,  A61K39/395 ,  C07K14/005

CPC classification number: C07K16/2833 ,  A61K39/3955 ,  C07K14/005 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/16034 ,  C12N2710/16631

Abstract: The present invention relates to therapeutic compounds, such as vaccines against avian diseases and in particular to DNA vaccines. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a DNA vaccine or used separately. Further described are pharmaceutical formulations, host cells and methods for producing the vaccines, as well as methods for the treatment or prevention of various diseases in animals, such as avians, such as cancers and infectious diseases.

Abstract translation: 本发明涉及治疗性化合物，例如针对禽类疾病的疫苗，特别是DNA疫苗。 本发明还涉及编码同二聚体肽的蛋白质构建体，该肽可以从DNA疫苗中释放或分开使用。 进一步描述的是药物制剂，宿主细胞和用于生产疫苗的方法，以及用于治疗或预防动物诸如禽类如癌症和感染性疾病的各种疾病的方法。

公开(公告)号：US20160002343A1

公开(公告)日：2016-01-07

申请号：US14737474

申请日：2015-06-11

Applicant: AbbVie Inc.

Inventor： Denise Karaoglu Hanzatian ,  Andrew D. Goodearl ,  Bernhard Klaus Mueller ,  Reinhold Mueller ,  Corinna Klein

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/2881 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/22 ,  C07K16/241 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2319/00 ,  Y02A50/466

Abstract: Engineered agents or multivalent and multispecific binding proteins capable of penetrating the cells or tissue of the blood-brain barrier (BBB) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

Abstract translation: 提供能够穿透血脑屏障（BBB）的细胞或组织的工程化剂或多价和多特异性结合蛋白，以及制备和用于预防，诊断和/或治疗疾病的方法。

公开(公告)号：US20160002324A1

公开(公告)日：2016-01-07

申请号：US14797719

申请日：2015-07-13

Applicant: Zoetis Belgium S.A.

Inventor： Susan E. Lacy ,  Jeffrey A. Barbon ,  Meha Chhaya ,  Emma Fung ,  Charles W. Hutchins ,  Diane M. Lang ,  Eve H. Barlow ,  Mary Leddy ,  Ravi Chari

IPC: C07K16/22

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/50 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/566

Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.

公开(公告)号：US09226484B2

公开(公告)日：2016-01-05

申请号：US14800263

申请日：2015-07-15

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lynn Macdonald ,  Sean Stevens ,  Cagan Gurer ,  Andrew J. Murphy ,  Karolina A. Meagher

IPC: A01K67/027

CPC classification number: C12N5/0606 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/02 ,  A01K2267/0381 ,  C07K16/00 ,  C07K16/18 ,  C07K16/461 ,  C07K16/462 ,  C07K2317/10 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/50 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/64 ,  C12N15/10 ,  C12N15/8509

Abstract: Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.

公开(公告)号：US20150376276A1

公开(公告)日：2015-12-31

申请号：US14758430

申请日：2013-12-20

Applicant: SEATTLE GENETICS, INC.

Inventor： Timothy S Lewis ,  Che-Leung Law

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein.

Abstract translation: 公开了特异性结合NTB-A的抗体，包括抗体药物偶联物。 还公开了使用抗NTB-A抗体来检测或调节表达NTB-A的细胞的活性（例如抑制增殖）以及诊断或治疗疾病或病症（例如癌症）的方法， 与表达NTB-A的细胞相关。 进一步公开的是使用抗NTB-A抗体药物缀合物治疗多发性骨髓瘤的方法，其任选地包括本文公开的抗NTB-A抗体。

公开(公告)号：US20150351371A1

公开(公告)日：2015-12-10

申请号：US14800257

申请日：2015-07-15

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lynn Macdonald ,  Sean Stevens ,  Cagan Gurer ,  Andrew J. Murphy ,  Karolina A. Meagher

IPC: A01K67/027

CPC classification number: C12N5/0606 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/02 ,  A01K2267/0381 ,  C07K16/00 ,  C07K16/18 ,  C07K16/461 ,  C07K16/462 ,  C07K2317/10 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/50 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/64 ,  C12N15/10 ,  C12N15/8509

Abstract: Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.

Abstract translation: 提供基因修饰的小鼠，其表达人λ变量（hVλ）序列，包括从内源小鼠λ轻链基因座表达hVλ序列的小鼠，从内源小鼠和kgr表达hVλ序列的小鼠; 轻链基因座和表达hVλ序列的小鼠，其中hVλ序列与小鼠恒定序列连接。 提供了可用于制备抗原结合蛋白的体细胞突变的人λ可变序列的来源的小鼠。 提供了包含人λ可变序列（包括人抗体）的抗原结合蛋白的组合物和方法。

公开(公告)号：US09204624B2

公开(公告)日：2015-12-08

申请号：US14498523

申请日：2014-09-26

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： John McWhirter ,  Cagan Gurer ,  Karolina A. Meagher ,  Lynn Macdonald ,  Andrew J. Murphy

IPC: A01K67/027 ,  C12P21/08 ,  C07K16/46 ,  C07K16/00

CPC classification number: A01K67/0278 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K2317/10 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/56 ,  C07K2317/64 ,  C12N15/1003

Abstract: Non-human animals, e.g., mammals, e.g., mice or rats, are provided comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence. The rearranged human immunoglobulin heavy chain variable region nucleotide sequence may be operably linked to a heavy or light chain constant region nucleic acid sequence. Also described are genetically modified non-human animals comprising an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, which may be operably linked to a light chain constant region nucleic acid sequence. Also provided are methods for obtaining nucleic acid sequences that encode immunoglobulin light chain variable domains capable of binding an antigen in the absence of a heavy chain.

Abstract translation: 提供非人动物，例如哺乳动物，例如小鼠或大鼠，其包含免疫球蛋白重链基因座，其包含重排的人免疫球蛋白重链可变区核苷酸序列。 重排的人免疫球蛋白重链可变区核苷酸序列可以可操作地连接到重链或轻链恒定区核酸序列。 还描述了遗传修饰的非人动物，其包含免疫球蛋白轻链基因座，其包含一个或多个但少于野生型数量的人免疫球蛋白轻链可变区基因片段，其可以可操作地连接到轻链恒定区核酸序列 。 还提供了获得编码在不存在重链时能够结合抗原的免疫球蛋白轻链可变结构域的核酸序列的方法。

公开(公告)号：US20150344590A1

公开(公告)日：2015-12-03

申请号：US14713251

申请日：2015-05-15

Applicant: ABBVIE INC.

Inventor： Tariq Ghayur ,  JiJie Gu ,  Maria Harris ,  Carrie Goodreau ,  Sonal Saluja

IPC: C07K16/46 ,  G01N33/68 ,  C07K16/24

CPC classification number: C07K16/468 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6845 ,  A61K47/6879 ,  C07K16/244 ,  C07K16/245 ,  C07K2317/31 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  G01N33/6869 ,  G01N2333/54 ,  G01N2333/545

Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

Abstract translation: 结合IL-1和bgr的工程化多价和多特异性结合蛋白 和/或IL-17，以及在预防，诊断和/或治疗疾病中的制备和用途的方法。

公开(公告)号：US20150322168A1

公开(公告)日：2015-11-12

申请号：US14241806

申请日：2012-10-16

Applicant: Crystal Bioscience Inc.

Inventor： William Don Harriman

IPC: C07K16/46 ,  A01K67/027

CPC classification number: C07K16/462 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2227/101 ,  A01K2227/102 ,  A01K2227/103 ,  A01K2227/107 ,  A01K2227/30 ,  A01K2267/01 ,  C07K16/005 ,  C07K16/468 ,  C07K2317/14 ,  C07K2317/23 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/64

Abstract: A transgenic non-human animal is provided. In certain embodiments, the animal comprises a genome comprising an immunoglobulin heavy chain locus comprising: a) a transcribed gene encoding a fusion protein comprising, from N-terminus to C-terminus: i. a scaffold comprising a first binding domain; and ii. a heavy chain constant region operably linked to the scaffold; wherein the scaffold is capable of specifically binding to a target in the absence of additional polypeptides; and b) a plurality of pseudogenes that are operably linked to the transcribed gene and that donate, by gene conversion, nucleotide sequence to the part of the transcribed gene that encodes the binding domain.

Abstract translation: 提供了一种转基因非人动物。 在某些实施方案中，动物包含包含免疫球蛋白重链基因座的基因组，其包含：a）编码融合蛋白的转录基因，其包含从N末端至C末端： 包含第一结合结构域的支架; 和ii。 可操作地连接到支架的重链恒定区; 其中所述支架能够在不存在另外的多肽的情况下特异性结合靶标; 和b）可操作地连接到转录基因并且通过基因转化将核苷酸序列提供给编码结合结构域的部分转录基因的多个假基因。